.STUDY HIGHLIGHT.06 August 2024.
A huge randomized measured test along with cisgender females highlights the obstacles of adherence to a day-to-day oral preexposure prevention program and illustrates that twice-yearly injection of lenacapavir can preserve efficient HIV deterrence levels over 6 months.